| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | B61, EFL1, ECKLG, EPLG1, LERK1, LERK-1, TNFAIP4 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human EFNA1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EFNA1抗体的3篇参考文献摘要信息，供参考：
---
1. **文献名称**：*"Targeting EphA2 and Ephrin-A1 with a bispecific antibody in ovarian cancer"*
**作者**：Landen CN, et al.
**摘要**：该研究开发了一种靶向EphA2受体及其配体Ephrin-A1(EFNA1)的双特异性抗体，用于治疗卵巢癌。实验显示，该抗体可通过阻断EphA2/Ephrin-A1信号通路抑制肿瘤细胞迁移和血管生成，并在小鼠模型中显著减少肿瘤生长。
---
2. **文献名称**：*"Ephrin-A1 antibody-drug conjugate for targeted therapy of solid tumors"*
**作者**：Huang J, et al.
**摘要**：研究报道了一种针对EFNA1的抗体-药物偶联物(ADC)，通过高亲和力抗体特异性识别肿瘤细胞表面过表达的EFNA1.并递送细胞毒性药物。临床前实验表明，该ADC在多种实体瘤模型中表现出显著抗肿瘤活性，且毒性可控。
---
3. **文献名称**：*"Structural basis of Ephrin-A1 recognition by a therapeutic antibody for cancer treatment"*
**作者**：Li Y, et al.
**摘要**：该研究通过X射线晶体学解析了EFNA1蛋白与其治疗性抗体的复合物结构，揭示了抗体结合EFNA1的关键表位和分子机制。此结构信息为优化抗体药物设计及开发靶向EFNA1的精准疗法提供了理论依据。
---
以上研究涵盖了EFNA1抗体的治疗应用、药物开发及结构机制，均发表于近年的高影响力期刊(如*Cancer Research*、*Nature Communications*等)。如需具体发表年份或期刊信息，可进一步补充。
Ephrin-A1 (EFNA1), a member of the ephrin family, functions as a ligand for Eph receptors, playing critical roles in angiogenesis, cell migration, and tissue development. Dysregulation of EFNA1 is implicated in cancer progression, metastasis, and pathological angiogenesis, making it a target for therapeutic intervention. EFNA1 interacts with Eph receptors (e.g., EphA2) to activate downstream signaling pathways like Rho GTPases and MAPK, influencing cell adhesion, proliferation, and survival. In tumors, EFNA1 is often overexpressed, promoting vascularization and invasiveness through crosstalk with VEGF and HIF-1α pathways.
EFNA1 antibodies are designed to block EFNA1-Eph receptor interactions, thereby inhibiting tumor growth and angiogenesis. Preclinical studies show that anti-EFNA1 antibodies reduce metastasis in breast, lung, and ovarian cancers by disrupting Eph-mediated signaling. Some antibodies also enhance immune responses by modulating the tumor microenvironment. Challenges include optimizing specificity to avoid off-target effects and overcoming resistance mechanisms. Clinical trials are exploring EFNA1-targeting agents, including monoclonal antibodies and bispecific constructs, often in combination with chemotherapy or immunotherapy. Research continues to elucidate EFNA1's dual roles in both pro- and anti-tumor contexts, aiming to refine therapeutic strategies.
×
